{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:08:12Z","timestamp":1762322892006},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,10,30]],"date-time":"2003-10-30T00:00:00Z","timestamp":1067472000000},"content-version":"vor","delay-in-days":2281,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Immunology"],"published-print":{"date-parts":[[1997,8]]},"abstract":"<jats:p>Tumour necrosis factor\u2010<jats:italic>&amp;alpha;<\/jats:italic> (TNF\u2010<jats:italic>&amp;alpha;<\/jats:italic>) and interleukin\u20101<jats:italic>&amp;beta;<\/jats:italic> (IL\u20101<jats:italic>&amp;beta;<\/jats:italic>) are pro\u2010inflammatory cytokines that play an important role in severe infections, whereas IL\u20101 receptor antagonist (IL\u20101ra) and IL\u201010 are anti\u2010inflammatory cytokines that counteract their effects. Chlorpromazine and dexamethasone protect mice against lethal endotoxaemia by decreasing circulating concentrations of TNF\u2010<jats:italic>&amp;alpha;<\/jats:italic> and IL\u20101<jats:italic>&amp;beta;<\/jats:italic>. We investigated whether administration of chlorpromazine or dexamethasone to human volunteers is able to modulate the lipopolysaccharide (LPS)\u2010stimulated cytokine production capacity in whole blood. Blood samples were taken before and several time\u2010points after medication. Circulating cytokine concentrations were low in all samples. LPS\u2010induced TNF\u2010<jats:italic>&amp;alpha;<\/jats:italic> and IL\u20101<jats:italic>&amp;beta;<\/jats:italic> production in whole blood was inhibited by dexamethasone treatment, while chlorpromazine had no effect. When peripheral blood mononuclear cells were stimulated <jats:italic>in vitro<\/jats:italic> with LPS, the addition of chlorpromazine (1\u2013100\u2003ng\/ml) had no modulatory action on TNF\u2010<jats:italic>&amp;alpha;<\/jats:italic>, IL\u20101<jats:italic>&amp;beta;<\/jats:italic>, IL\u20101ra or IL\u201010 synthesis. The chlorpromazine concentrations measured in circulation of volunteers were eight to 40 times lower than the concentrations shown to be effective in mice. In conclusion, chlorpromazine inhibits TNF\u2010<jats:italic>&amp;alpha;<\/jats:italic> and IL\u20101<jats:italic>&amp;beta;<\/jats:italic> production in mice at concentrations that cannot be reached in humans, thus precluding its usage in clinical anti\u2010cytokine strategies. In contrast, dexamethasone is an effective inhibitor of pro\u2010inflammatory cytokine production.<\/jats:p>","DOI":"10.1046\/j.1365-2567.1997.00285.x","type":"journal-article","created":{"date-parts":[[2003,11,2]],"date-time":"2003-11-02T15:43:53Z","timestamp":1067787833000},"page":"548-552","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The effects of dexamethasone and chlorpromazine on tumour necrosis factor\u2010<i>&amp;alpha;<\/i>, interleukin\u20101<i>&amp;beta;<\/i>, interleukin\u20101 receptor antagonist and interleukin\u201010 in human volunteers"],"prefix":"10.1111","volume":"91","author":[{"given":"M. W. P.","family":"BLEEKER","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. G.","family":"NETEA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"KULLBERG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"VAN DER VEN\u2010JONGEKRIJG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. W. M.","family":"VAN DER MEER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,30]]},"container-title":["Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2567.1997.00285.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2567.1997.00285.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2567.1997.00285.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:02:11Z","timestamp":1694419331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2567.1997.00285.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,8]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,8]]}},"alternative-id":["10.1046\/j.1365-2567.1997.00285.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2567.1997.00285.x","archive":["Portico"],"relation":{},"ISSN":["0019-2805","1365-2567"],"issn-type":[{"value":"0019-2805","type":"print"},{"value":"1365-2567","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,8]]},"assertion":[{"value":"2003-10-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}